



Level 17, 201 Miller St
North Sydney
NSW 2060 Australia
Ph: +61 2 8923 2512
Fax: +61 2 8923 2525

www.ritract.com
abn: 28 106 353 253

ASX ANNOUNCEMENT

Rittract in advanced FDA approval discussions to permit US sales

Sydney, Australia: 28 March 2006: Australia's retractable safety syringe company, Rittract Limited (ASX: RTL), today reported that discussions on approval of its range of safety syringe products with the United States regulatory body, the Food & Drug Administration (FDA) had considerably advanced.

Rittract Managing Director, Mr Rupert Northcott, said the talks reflected the significant ongoing activity associated with the company's plans to expedite the commercialisation of Rittract's highly innovative Australian-designed automatic retractable safety syringe products.

"Rittract is in the advanced stages of ongoing discussions with the FDA to gain approval to sell the Rittract safety syringe in the US market.

"We are confident of a positive outcome and will keep the market fully informed on a timely basis," Mr Northcott said.

"Our focus is to fulfil existing forward orders for our range of safety syringes as soon as possible."

"We are confident we are on track to capture a significant market share worldwide due to the innovative and superior nature of our product range and believe that Rittract is well positioned to become an early and dominant leader in the growing global retractable safety syringe market," he said.

Mr Northcott said Rittract had already made major inroads into the conservatively estimated five billion-unit per annum global safety syringe market. These achievements included:

- Forward orders from B.Braun, a major global device manufacturer and distributor
- Appointment of Verna Group as UK distributor with fast track into National Health Service (NHS) listing
- Manufacturing of commonly used three, five and 10ml designs
- Trials of one ml molds underway
- Delivery of the first semi-automatic assembly machine to Rittract's manufacturing partner in China.

Mr Northcott said it was also important to note Rittract (understood it) was the only company in the world with the:

- first commercially available automatic retractable syringe that allows use of standard needles
- first automatic retractable syringe that allows full user control of the needle retraction
- largest range of safety syringe sizes that take standard needles.

"Rittract's range of one, three, five and 10 ml syringes will allow the company to provide a safety solution for a clear, unfulfilled world demand," Mr Northcott said.

About Rittract

Rittract Limited's patented unique technology is designed to meet world demand for innovative, safety injection solutions in global health markets. Rittract's immediate market are health care workers at the front line of the international medical community, with the primary aim being to specifically protect them from needlestick injury. The company's vision is to help create a safer world by replacing every non-safety needle and syringe with the Rittract safety technology.

For more information, please contact:

Mr Rupert Northcott
Managing Director
Rittract Limited
Tel: (02) 8923 2511 or 0411 069 000